# DSTrain Ethics Form, Call 1

* This Ethics Self-Assessment form is a mandatory element of the application for a DSTrain postdoctoral research fellow position. Projects cannot commence before all relevant approvals are in place. The DSTrain Programme adheres to the European Commission’s ethical standards laid out for Horizon Europe. All projects funded by DSTrain must follow both EU and national/local ethics regulations.
* If your proposal raises any of the ethical concerns (i.e., you answer YES to any question) in PART A, please include more details in PART B, including plans for how to acquire necessary permissions or documentation.
* Applicants must also include a brief discussion of relevant ethical issues in the project description.
* Please save the completed document in the name format “6\_Surname\_Ethical issues form” and substitute “Surname” for your last name.
* Please remember to sign the completed form. Electronic signature is acceptable.
* If you have further questions, please contact the DSTrain Project Management Office per e-mail: [contact-dstrain@mn.uio.no](mailto:contact-dstrain@mn.uio.no).

## PART A Ethics Issues Table

|  |  |  |
| --- | --- | --- |
| **Human Embryonic Stem Cells and Human Embryos** | **Yes** | **No** |
| Does this activity involve Human Embryonic Stem Cells (hESCs)? |  |  |
| Does this activity involve the use of human embryos? |  |  |
| **Humans** | **Yes** | **No** |
| Does this activity involve human participants? |  |  |
| Does this activity involve interventions (physical also including imaging technology, behavioural treatments, etc.) on the study participants? |  |  |
| Does this activity involve conducting a clinical study as defined by the Clinical Trial [Regulation (EU 536/2014)](https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.L_.2014.158.01.0001.01.ENG)? (using pharmaceuticals, biologicals, radiopharmaceuticals, or advanced therapy medicinal products) |  |  |
| **Human Cells (not covered by section 1)** | **Yes** | **No** |
| Does this activity involve the use of human cells or tissues? |  |  |
| **Personal Data** | **Yes** | **No** |
| Does this activity involve processing of personal data? |  |  |
| Does this activity involve further processing of previously collected personal data (including  use of preexisting data sets or sources, merging existing data sets)? |  |  |
| Is it planned to export personal data from the EU to non-EU countries? |  |  |
| Is it planned to import personal data from non-EU countries into the EU or from a non-EU country to another non-EU country? |  |  |
| Does this activity involve the processing of personal data related to criminal convictions or  offences? |  |  |
| **5. Animals** | **Yes** | **No** |
| Does this activity involve animals? |  |  |
| **6. Non-EU Countries** | **Yes** | **No** |
| Will some of the activities be carried out in non-EU countries? |  |  |
| In case non-EU countries are involved, do the activities undertaken in these countries raise potential ethics issues? |  |  |
| It is planned to use local resources (e.g. animal and/or human tissue samples, genetic material, live animals, human remains, materials of historical value, endangered fauna or flora samples, etc.)? |  |  |
| Is it planned to import any material (other than data) from non-EU countries into the EU or from a non-EU country to another non-EU country? For data imports, see section 4. |  |  |
| Is it planned to export any material (other than data) from the EU to non-EU countries? For data exports, see section 4. |  |  |
| Does this activity involve [low and/or lower middle income countries](https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/global-code-of-conduct-for-research-in-resource-poor-settings_he_en.pdf), (if yes, detail the benefit sharing actions planned in the self-assessment) |  |  |
| Could the situation in the country put the individuals taking part in the activity at risk? |  |  |
| **7. Environment, Health and Safety** | **Yes** | **No** |
| Does this activity involve the use of substances or processes that may cause harm to the  environment, to animals or plants (during the implementation of the activity or further to the use of the results, as a possible impact)? |  |  |
| Does this activity deal with endangered fauna and/or flora/protected areas? |  |  |
| Does this activity involve the use of substances or processes that may cause harm to humans, including those performing the activity (during the implementation of the activity or further to the use of the results, as a possible impact)? |  |  |
| **8. Artificial Intelligence** | **Yes** | **No** |
| Does this activity involve the development, deployment and/or use of Artificial Intelligence systems? |  |  |
| **9. Other Ethics Issues** | **Yes** | **No** |
| Are there any other ethics issues that should be taken into consideration? |  |  |
| **Summary** | **Yes** | **No** |
| *I confirm that I have taken into account all ethics issues above and that, if any ethics issues apply, I will complete the ethics self-assessment as described in the guidelines* [*How to Complete your Ethics Self-Assessment*](https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/how-to-complete-your-ethics-self-assessment_en.pdf) |  |  |

## PART B Ethics Self-Assessment

*If you have identified any ethical issues in Part A, you must describe these further here.*

|  |
| --- |
| **Ethical dimension of the objectives, methodology and likely impact** |
| *If applicable, describe how you intend to address the issues raised in Part A (e.g., consent).* |

|  |
| --- |
| **Compliance with ethical principles and relevant legislations** |
| *If applicable, address how the proposal meets the national legal and ethical requirements of the country or countries where the tasks in question are to be carried out.* |

Date Name and signature of applicant